Table 2 Live virus neutralization assessed by PRNT50 in phase 3

From: An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

 

GEMCOVAC-OM (N = 271)

ChAdOx1 nCoV-19 (N = 133)

Baseline GMT (95% CI)a

623.9 (533.3–729.9)

775.3 (620.2–969.2)

Day 29 GMT (95% CI)a

1,099.9 (1,000.0–1,209.9)

754.9 (631.5–902.5)

GMFRb

1.76

0.97

P valuec

<0.0001

0.1490

LSGMR (GEMCOVAC-OM/ChAdOx1 nCoV-19) 95% CId

1.58 (1.36–1.84)

 

P valued

<0.0001

 

Seroconversion assessed by ≥2-fold rise from baseline, % (95% CI)e

39.5 (33.6–45.5)

19.5 (13.1–27.3)

Difference in seroconversion (95% CI)

19.93 (10.5–28.4)f

 

Day 90 GMT (95% CI)a

754.0 (682.1–833.6)

383.1 (319.4–459.6)

GMFRb

1.21

0.49

P valuec

0.5618

<0.0001

LSGMR (GEMCOVAC-OM/ChAdOx1 nCoV-19) 95% CId

2.09 (1.75–2.49)

 

P valued

<0.0001

 
  1. aThe 95% CI of GMT was calculated by taking the log base 10 transformed titers.
  2. bGMFR was calculated as post/pre of neutralizing antibody titers.
  3. cP value for GMFR was calculated using a two-sided Wilcoxon signed-rank test.
  4. dLSGMR (95% CI) and P value was calculated using ANCOVA with baseline values as covariates.
  5. eThe 95% CIs were calculated by the Clopper–Pearson method.
  6. fTwo-sided 95% CIs for difference in proportion of participants between groups were calculated using the Miettinen–Nurminen method.
Back to article page